비타민 K길항제가 아닌 항응고제를 복용하는 환자들을 위한 치과 치료
Dental Treatment for Patients with Non-Vitamin K Antagonist Oral Anticoagulant
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
The vitamin K antagonist (VKA), cumadin, or warfarin, is the only antithrombotic drug that can be orally administered and has excellent effective for decades. However, it is cumbersome to periodically inspect the prothrombin time (PT) order to maintain adequate concentrations that do not cause bleeding, takes a few days to indicate therapeutic effects, gets affected by several factors such as food and drugs etc, and narrow in the therapeutic range. Although recently in development, the non-vitamin K antagonist anticoagulants(NOACs) exhibit a rapid onset of action and have relatively short half- lives compared to Coumadin. Because of these pharmacokinetic properties, it is possible to modify an individual's anticoagulation status quite rapidly, minimizing the period where the anticoagulation activity is therapeutically sub-optimal. And the short half -lives of these drug allow for the relatively rapid reduction of their anticoagulation effects. There are currently no published clinical trials specifically assessing the bleeding risks associated with dental procedures for patients taking the NOACs. It is not necessary to interrupt NOAC medication for dental procedures that are likely to cause bleeding, but which have a low risk of bleeding complications. Because the bleeding risk for these procedures is considered to be low, the balance of effects is in favour of continuing the NOAC treatment without modification, to avoid increasing the risk of a thromboembolic event. The patients should be advised to miss(apixaban or dabigatran) or delay(rivaroxaban) a dose of their NOAC prior to dental procedures that are likely to cause bleeding and which have a higher risk of bleeding complications. Because the risk of bleeding complications for these procedures is considered to be higher, the balance effects is in favour of missing or delaying the pre-treatment NOAC dose. The interruption is only for a short time to minimize the effect on thromboembolic risk,
Abstract
The vitamin K antagonist (VKA), cumadin, or warfarin, is the only antithrombotic drug that can be orally administered and has excellent effective for decades. However, it is cumbersome to periodically inspect the prothrombin time (PT) order to maintain adequate concentrations that do not cause bleeding, takes a few days to indicate therapeutic effects, gets affected by several factors such as food and drugs etc, and narrow in the therapeutic range. Although recently in development, the non-vitamin K antagonist anticoagulants(NOACs) exhibit a rapid onset of action and have relatively short half- lives compared to Coumadin. Because of these pharmacokinetic properties, it is possible to modify an individual's anticoagulation status quite rapidly, minimizing the period where the anticoagulation activity is therapeutically sub-optimal. And the short half -lives of these drug allow for the relatively rapid reduction of their anticoagulation effects. There are currently no published clinical trials specifically assessing the bleeding risks associated with dental procedures for patients taking the NOACs. It is not necessary to interrupt NOAC medication for dental procedures that are likely to cause bleeding, but which have a low risk of bleeding complications. Because the bleeding risk for these procedures is considered to be low, the balance of effects is in favour of continuing the NOAC treatment without modification, to avoid increasing the risk of a thromboembolic event. The patients should be advised to miss(apixaban or dabigatran) or delay(rivaroxaban) a dose of their NOAC prior to dental procedures that are likely to cause bleeding and which have a higher risk of bleeding complications. Because the risk of bleeding complications for these procedures is considered to be higher, the balance effects is in favour of missing or delaying the pre-treatment NOAC dose. The interruption is only for a short time to minimize the effect on thromboembolic risk,
참고문헌 (20)
- Shapiro SS, "Treating thrombosis in the 21st century", N Engl J Med, 349, pp.1762~1764 (2003)
- Sinauridze E. I., "Anticoagulant therapy : basic principles, classic approaches and recent developments", Blood Coagul Fibrinolysis, 23, pp.482~493 (2012)
- righton T, "New oral anticoagulant drugs- mechanisms of action", Aust Prescr, 33, pp.38~41 (2010)
- Connolly SJ, "Dabigatran versus warfarin in patients with atrial fibrillation", N Engl J Med, 361, pp.1139~1151 (2009)
- Patel MR, "Rivaroxaban versus warfarin in nonvalvular atrial fibrillation", N Engl J Med, 365, pp.883~891 (2011)
- Granger CB, "Apixaban versus warfarin in patients with atrial fibrillation", N Engl J Med, 365, pp.981~992 (2011)
- Giugliano RP, "Edoxaban versus warfarin in patients with atrial fibrillation", N Engl J Med, 369, pp.2093~2104 (2013)
- Lip GY, "Non-vitaminK antagonist oral anticoagulants : an appeal for consensus on terminology", Chest, 145, pp.1177~1178 (2014)
- Mani H, "New oral anticoagulants in patients with nonvalvular atrial fibrillation : a review of pharmacokinetics, safety, efficacy, quality of life, and cost effectiveness", Drug Des Devel Ther, 8, pp.789~798 (2014)
- Mueck W, "Co-administration of rivaroxaban with drugs that share its elimination pathways : pharma cokinetic effects in healthy subjects", Br J Clin Pharmaocl, 76, pp.455~466 (2013)
- Wang L, "In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies", Drug Metab Dispos, 38, pp.448~458 (2010)
- F. Schiele, "A specific antidote for dabigatran: functional and structural characterization", Blood, 121, pp.3554~3562 (2013)
- DeWald TA, "The pharmacology of novel oral anticoagulants", J Thromb Thrombolysis, 37, pp.217~233 (2014)
- Wang L, "In vitro assessment of met abolic drug-drug interaction potential of apixaban through cy tochrome P450 phenotyping, inhibition, and induction studies", Drug Metab Dispos, 38, pp.448~458 (2010)
- A. Greinacher, "Reversal of anticoagulants: an overview of current developments", Thromb. Haemost, 113, pp.931~942 (2015)
- C.V. Pollack Jr., "Idarucizumab for Dabigatran Reversal", N. Engl. J. Med, 373, pp.511~520 (2015)
- G. Lu, "A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa", Nat.Med, 19, pp.446~451 (2013)
- K. Ghadimi, "Andexanet alfa for the reversal of factor Xa inhibitor related anticoagulation", Expert. Rev. Hematol, 9, pp.115~122 (2016)
- M.L.G. Crowther, "A phase 2 randomized, double-blind, placebo-controlled trial demonstrat ing reversal of edoxabaninduced anticoagulation in healthy subjects by andexanet alfa (PRT064445): a universal antidote for factor Xa (fXa) inhibitors", Blood, 124, pp.4269~ (2014)
- "Managementof dental patients taking anticoagulants or antiplatelet drugs: dental clinical guidance"[URL]